Recursion Pharmaceuticals shares rise on FDA approval of REC-4881 Phase 3 trial design
RXRX Recursion Pharmaceuticals Inc
$2.83 +3.86%
View chart & analysis → - 1Recursion Pharmaceuticals announced that the US FDA has approved the Phase 3 trial design for REC-4881.
- 2Recursion Pharmaceuticals shares rose 5.4% as of 11:59 AM ET.
- 3The REC-4881 Phase 3 clinical trial is scheduled to begin in the second half of next year.
So what's the key point?
Recursion Pharmaceuticals' stock rose 5.4% after the US FDA approved its new drug trial plan. The company will begin full-scale testing in the second half of next year.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.